Hospital Segment is Expected to be Fastest Growing During Forecast Period for MEA Region                   

According to a new market research study on “MEA Latent TB Detection Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Test and End User” is expected to reach US$ 60.82 million by 2027 from US$ 47.39 million in 2020. The market is estimated to grow at a CAGR of 3.6% from 2020 to 2027. The report provides trends prevailing in the MEA latent TB detection market along with the drivers and restraints pertaining to the market growth. Burgeoning market in emerging economies and rising advancements in tuberculosis diagnosis are the major factor driving the growth of the MEA latent TB detection market. However, availability of multidrug resistant tuberculosis (MDR-TB) hinders the growth of MEA latent TB detection market.  

In case of COVID-19, MEA is highly affected especially South Africa. Economic uncertainties and ongoing conflicts are worsening the condition in the region. For instance, countries such as Syria, Libya, and Yemen are suffering violent conflict and cannot implement any public health measures. Iran was in deep economic recession due to the US sanctions. Also, the major source of economic stabilization in Middle East countries is oil production and export. However, the recent pandemic is causing turbulence to the economies of the Middle East region. A sudden drop in domestic and external demand for goods and products, especially crude oil, and halted production due to labor shortage, are major impacts observed in the region. Additionally, tightened financial condition is also decreasing the economic activities in the region. Since the beginning of 2020, the COVID-19 pandemic has caused enormous health, social and economic impacts, which are likely to continue in 2021 and beyond. Even after some of these impacts have been mitigated or contained, there will be medium- and longer-term consequences, including for the TB epidemic and response. The pandemic threatens to reverse the progress made towards TB targets by the end of 2019. With many laboratory services under acute pressure, new TB case notifications in some places have dropped by up to 75%.

The MEA latent TB detection market has been segmented into the test, end user, and country. Based on test, the market has been segmented into tuberculin skin test (TST) and interferon gamma released assay (IGRA). The tuberculin skin test (TST) segment dominated the MEA latent TB detection market in 2019 and interferon gamma released assay (IGRA) segment is expected to be fastest growing during forecast period. Based on end user, the market has been segmented into the hospitals, diagnostic centers, laboratories, and others. The hospitals segment dominated the MEA latent TB detection market in 2019 and same segment is expected to be fastest growing during forecast period. Based on country, the market has been segmented into the UAE, Saudi Arabia, South Africa, and rest of MEA.  

Abbott; ARKRAY, Inc.; BD; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Oxford Immunotec Ltd; QIAGEN; and Serum Institute of India Pvt. Ltd. are among the leading companies in the MEA latent TB detection market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, The Oxford Immunotec Ltd has entered into a long-term agreement to supply its T-SPOT.TB test and associated accessories to the Stop TB Partnership – Global Drug Facility (GDF). The GDF is the largest provider of TB medicines, diagnostics and laboratory supplies worldwide).                       

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com